Dynor Pharmaceuticals Private Limited
About Dynor Pharmaceuticals Private Limited
Data last updated:
Dynor Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 18 March 1996 and has been in existence for over 30 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24231DL1996PTC077290. Its GSTIN is 07AAACD4009R1ZH (Delhi).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors Bharat Bhushan Tuteja (Managing Director) and Manik Tuteja.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 10/38 Geeta Colony, New Delhi, Delhi, India – 110031.
As per the financials filed for FY 2020, the company reported a revenue of ₹38.38 Lakh, a decline of 16% compared to the previous year. For the same year it recorded a net profit of ₹34,476 (net margin 0.9%) and EBITDA of ₹91,237 (EBITDA margin 2.4%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 5% over five years.
As per MCA filings, the company has open charges of ₹12 Lakh on record. Court records list 2 cases involving the company, including 2 filed against it.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address10/38 Geeta Colony, New Delhi, Delhi, India – 110031
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Dynor Pharmaceuticals Private Limited
The main business activity of Dynor Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Dynor Pharmaceuticals Private Limited FY 2025 filings available
Dynor Pharmaceuticals Private Limited reported revenue of ₹38.38 Lakh (down 16% YoY) for FY 2020.
Compounded Annual Growth Rate (CAGR) of Dynor Pharmaceuticals Private Limited
Revenue fell 16% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 5%. EBITDA fell 12% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Dynor Pharmaceuticals Private Limited
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹38.38 Lakh | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹91,237 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹34,476 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Dynor Pharmaceuticals Private Limited
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.9% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Dynor Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Auditor Details of Dynor Pharmaceuticals Private Limited
Dynor Pharmaceuticals Private Limited is audited by JAIN ARUN & CO for the financial year 2020.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| JAIN ARUN & CO | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Dynor Pharmaceuticals Private Limited
Dynor Pharmaceuticals has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bharat Bhushan Tuteja | Managing Director | 18 Mar 1996 | 30 Years 6 Months | Current |
| Manik Tuteja | Director | 20 Oct 2022 | 3 Years 11 Months | Current |
Ownership and Shareholding of Dynor Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Dynor Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 May 2009 | State Bank of India | ₹12 Lakh | Open |
Total charge records: 1 View all charges
Legal Cases of Dynor Pharmaceuticals Private Limited
Dynor Pharmaceuticals Private Limited has 2 court cases on record: 2 filed against it. All cases are disposed. Status as checked between 29 Sep 2026 and 02 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 2 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, North East, Delhi | Court case (Civ Suit) | Filed against the company by an individual | Disposed |
| District court, East, Delhi | Court case (Civ Suit) | Filed against the company by an individual | Disposed |
Full case history
All 2 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Dynor Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Dynor Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Dynor Pharmaceuticals Private Limited
Dynor Pharmaceuticals Private Limited has 5 board changes on record since 1996: 2 appointments and 3 cessations. The latest: Manik Tuteja ceased to be Additional Director on 30 Sep 2023.
Credit Ratings, Litigation & Regulatory Alerts for Dynor Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Dynor Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Dynor Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Dynor Pharmaceuticals Private Limited
Dynor Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACD4009R1ZH | Delhi | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Dynor Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dynor Pharmaceuticals Private Limited
Dynor Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 18 March 1996 (30+ years old) and is registered under CIN U24231DL1996PTC077290.
Dynor Pharmaceuticals reported revenue of ₹38.38 Lakh for FY 2020 (down 16% YoY).
Dynor Pharmaceuticals has 2 current directors:
- Bharat Bhushan Tuteja - Managing Director
- Manik Tuteja - Director
Dynor Pharmaceuticals reported a net profit of ₹34,476 (net margin 0.9%) and EBITDA of ₹91,237 (EBITDA margin 2.4%) for FY 2020, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Dynor Pharmaceuticals is 2% over three years and 5% over five years. In the latest year (FY 2020) revenue fell 16%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Dynor Pharmaceuticals is 07AAACD4009R1ZH, registered in Delhi.
The CIN (Corporate Identification Number) of Dynor Pharmaceuticals is U24231DL1996PTC077290. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dynor Pharmaceuticals has 2 court cases on record: 2 filed against it.
Dynor Pharmaceuticals was incorporated on 18 March 1996, making it 30+ years old. It is registered with the Registrar of Companies, Delhi.
Manik Tuteja ceased to be Additional Director on 30 Sep 2023. Jatinder Kumar ceased to be Director on 20 Oct 2022. Manik Tuteja was appointed as Director on 20 Oct 2022. Dynor Pharmaceuticals has 5 board changes on record in total.